Benzinga | Jan 10, 2022 09:45AM EST

US Health & Human Secretary Says Given 50% Price Drop Of Biogen's Aduhelm, There Is Compelling Basis For Centers For Medicare Services To Reexamine Previous Recommendation On Aduhelm

-Reuters